HAEMOSTATIC DEFECTS IN CHRONIC KIDNEY DISEASE
Keywords:
CKD, D.Dimer, BT, PT, APTT, ThrombocytopeniaAbstract
Objective: To study Haemostatic defects in stage III and stage IV chronic kidney disease and to study coagulation
marker in these patients.
Material and Methods: This study was conducted in the Nephrology and Haematalogy Department of Shaikh Zayed
Hospital, Lahore from June 2010 to December 2010. The study included a total of 150 patients, 50 for stage III chronic
kidney disease, 50 for stage IV chronic kidney disease and 50 for control group. Bleeding time prothrombin time,
APTT, platelet count and D-Dimer were performed on these patients.
Results: A significantly elevated level of D-Dimer was found in 93% of the patients of stage III and stage IV chronic
kidney disease. For stage III P. value .001 and for stage IV P. value .001 significantly elevated as compared to the
control group less than 250ng /ml. Both PT and APTT for stage III and stage chronic kidney disease were within
normal range. Bleeding time in stage III was within normal range, while in stage IV only 5 out of 50 patients had
prolonged bleeding time. Which was significantly elevated as compared to control group (P. value <.002) platelet
count in stage III, only 5 patients out of 50, had thrombocytopenia, while in stage IV only 9 out of 50 patient had low
platelet count. Mean platelet count in stage III was 118.40 x 103/?l and in stage IV 115.44 x 103/?l thrombocytopenia
seen in stage III and stage IV showed significant association with to disease of when compared with normal control
group stage III P. value < .004 stage IV P <.005.
Conclusion: Chronic kidney disease both stage III and stage IV is assoated with coagulation abnormalities and
bleeding disorder. So watch the patients closely with chronic kidney disease to avoid complication of bleeding
tendency or thromboembolic phenomenon.
Downloads
Published
How to Cite
Issue
Section
License
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.
